USANA Q2 2026 earnings report shows revenue down 16% to $209.3M, impacted by a $29M goodwill impairment. EPS loss of $0.93 misses estimates by $0.37. (158)
USANA Health Sciences Inc. reported Q2 2026 revenue of $209.3 million, down 16% year-over-year and below the $222.1 million consensus. A non-cash goodwill impairment charge of $29 million significantly impacted financial results, highlighting ongoing challenges in the company’s emerging brands, particularly Haya and Rise Wellness.
Key Takeaways
- Revenue declined to $209.3 million, down 16% YoY and 18% sequentially, attributed mainly to a goodwill impairment charge.
- Goodwill impairment of $29 million reflects underperformance and revised valuation assumptions affecting future growth outlook.
- Earnings per share (EPS) reported at a loss of $0.93, missing the consensus estimate of a loss of $0.56 by $0.37.
- Free cash flow reached $20 million, showing solid financial management amidst operational disruptions.
- China's sales showed signs of recovery after a strong incentive program, but North Asia revenues fell 20%, necessitating leadership changes.
Revenue Decline Driven by Impairment Charges
USANA's revenue of $209.3 million for Q2 2026 represented a 16% decrease compared to $248.4 million in Q2 2025 and an 18% drop from the previous quarter’s $254.2 million. This decline was primarily driven by a $29 million non-cash goodwill impairment charge related to the Haya brand, which management attributed to its current underperformance and adjustments in market forecasts.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $209.3M | -16% | -18% |
| EPS | -$0.93 | N/A | N/A |
| Free Cash Flow | $20M | N/A | N/A |
Challenges and Future Outlook for Haya and Rise Wellness
The company acknowledged that Haya faced a tougher digital marketing environment, impacting its subscriber growth. Despite this, management expressed confidence in the brand’s long-term potential due to its established market presence and upcoming product expansions. However, they now project that Haya’s net sales for the year will be lower than previously expected.
Conversely, Rise Wellness encountered packaging-related issues that disrupted sales, although the team is optimistic about recovering these losses. The company has plans for new product launches that could help regain momentum.
“We recognize that the path to building a diversified omnichannel health and wellness company will not always be linear,” said Kevin Guest, CEO, emphasizing the need for discipline in navigating these challenges.
Guidance Update Reflects Near-Term Challenges
Management revised their full-year guidance downward due to anticipated difficulties in Haya and Rise Wellness. They cited the need to adjust expectations in the context of a more expensive direct-to-consumer marketing environment. The core nutritional segment, however, is expected to perform in line with prior expectations, suggesting stability in that area amidst broader challenges.
Analyst Q&A Highlights Concerns and Optimism
During the analyst Q&A, Kevin Guest highlighted China as a bright spot, indicating that the market is showing signs of recovery. He noted, “Our president there, Peter, is doing a fantastic job and my confidence has never been higher in our Chinese leadership.” However, concerns were raised about the 20% revenue decline in North Asia, which the company attributed to a leadership transition and market dynamics.
Additionally, analysts probed the potential for diversifying marketing strategies beyond traditional channels like Meta, particularly exploring platforms such as TikTok for better customer engagement. Management confirmed efforts are underway to adapt their marketing strategy in light of these challenges.
Frequently Asked Questions
Did USANA Health Sciences Inc beat earnings estimates in Q2 2026?
No, USANA reported an EPS loss of $0.93, which missed the consensus estimate of a loss of $0.56 by $0.37.
What was the reason for the revenue decline in Q2 2026?
The revenue decline of 16% was primarily driven by a $29 million goodwill impairment charge related to Haya, coupled with challenges in the direct-to-consumer segment.
How is USANA's performance in China?
USANA reported a recovery in sales in China, attributed to a strong incentive program that has built momentum among brand partners and customers in that market.
What challenges is Haya facing?
Haya is experiencing a tougher digital marketing environment, leading to lower subscriber growth and revised sales expectations for the year.
What is the outlook for Rise Wellness?
Despite short-term disruptions due to packaging issues, management remains optimistic about Rise Wellness's long-term potential, supported by new product launches and expanding retail relationships.
In conclusion, USANA is navigating significant short-term challenges while maintaining a focus on long-term growth strategies. The company's ability to stabilize its emerging brands and enhance its core nutritional business will be crucial in the upcoming quarters.
This analysis is based on public earnings call materials and is not investment advice.
